• Fangchinoline, TFEB, and H1N1 Infection

  2026-08-12

  The reference study identifies fangchinoline as a lysosome-targeted host-directed antiviral that restores TFEB-dependent lysosomal gene expression and restricts H1N1 infection. Its most important mechanistic insight is that lysosomal alkalinization, altered autophagic flux, and impaired endolysosomal trafficking converge to inhibit viral entry rather than merely suppressing later replication.

• Notch1–YY1–ICAM1 Axis in HCC Immunotherapy

  2026-08-12

  The reference study identifies the Notch1–YY1–ICAM1 pathway as a mechanistic determinant of immunotherapy response in hepatocellular carcinoma. Its findings suggest that suppressing YY1 can restore ICAM1-dependent CD8+ T-cell cytotoxicity and improve PD-L1 blockade without the broader toxicity concerns associated with direct Notch1 inhibition.

• Dicloxacillin Activity Against Intracellular S. aureus

  2026-08-11

  The reference study combined THP-1 cell assays with a murine peritonitis model to compare dicloxacillin activity against intracellular and extracellular Staphylococcus aureus. Its central practical finding was that free-drug exposure above the MIC, expressed as fT>MIC, best predicted efficacy in both bacterial compartments, while sampling time strongly influenced extracellular results.

• GluN2A/2B Control Trigeminal Allodynia in TMJ Inflammation

  2026-08-11

  This study identifies distinct roles for GluN2A and GluN2B in linking trigeminal ganglion sensitization with connexin and pannexin signaling during temporomandibular joint inflammation. Its combination of conditional knockout, behavioral testing, satellite glial cell experiments, and pathway analysis clarifies how NMDAR-dependent cell coupling may contribute to orofacial inflammatory allodynia.

• Regorafenib: From Kinase Breadth to Melanoma Biology

  2026-08-10

  Regorafenib (BAY 73-4506) is more than a broad-spectrum kinase tool: emerging melanoma data connect its anti-invasive activity to RRM2 suppression and ERK/E2F3 signaling. This thought-leadership guide translates that mechanism into practical strategies for angiogenesis research, cancer biology research, and translational model development.

• Multianimal MRI for Pancreatic Tumor Monitoring

  2026-08-09

  Kempinska and colleagues describe a four-chamber MRI workflow that enables high-resolution imaging of up to four KPC mice in one acquisition, improving the efficiency of pancreatic tumor detection and longitudinal measurement. The protocol was also used as a proof-of-concept framework for evaluating gemcitabine treatment response, linking reproducible imaging endpoints with preclinical therapeutic studies.

• WIP1/PPM1D, p38 MAPK, and AKI Pyroptosis

  2026-08-08

  The reference study identifies WIP1/PPM1D as a negative regulator of p38 MAPK-dependent renal tubular pyroptosis during sepsis-associated acute kidney injury. By combining injury models, single-cell sequencing, patient tissue analysis, and pharmacological inhibition, it shows that CCT007093 intensifies inflammatory cell death through p38 MAPK activation, providing a mechanistic framework for studying the PPM1D signaling pathway in kidney injury.

• A-1210477: MCL-1 Inhibitor Workflow Guide

  2026-08-07

  A-1210477 provides a selective in vitro route to test whether cancer cells rely on MCL-1-mediated survival rather than merely showing nonspecific cytotoxicity. This practical guide connects stock preparation, dose-response design, mitochondrial apoptosis assays, combination testing, and troubleshooting for more reproducible cancer research.

• Silymarin & Silybin A: Optimized Workflows for Liver Researc

  2026-08-07

  Silybin A, the bioactive powerhouse within Silymarin, unlocks reproducible, high-fidelity models of hepatoprotection and metabolic enzyme modulation. This guide translates cutting-edge chemistry and best practices into actionable protocols, troubleshooting insights, and comparative advantages for bench researchers. Learn how APExBIO's Silybin A reshapes liver disease and oxidative stress workflows.

• Fingolimod (FTY720): Translational Immunomodulation Beyond M

  2026-08-06

  Explore how Fingolimod (FTY720) advances immunomodulatory research far beyond multiple sclerosis. This article uncovers its mechanism, translational value in in vivo lymphocyte manipulation, and practical assay considerations, offering distinctive insights for advanced immunology and oncology studies.

• H-89 (SKU BA3584): Reliable PKA Inhibition for Cell Assays

  2026-08-06

  This article addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays, highlighting how H-89 (SKU BA3584) provides data-backed, reproducible solutions for cAMP-dependent protein kinase inhibition. Drawing on recent literature and real-world scenarios, it guides biomedical researchers on protocol optimization, data interpretation, and product selection using APExBIO's H-89.

• Rising Macrolide Resistance in Pediatric Mycoplasma pneumoni

  2026-08-05

  A recent study from Beijing demonstrates a 100% in vitro resistance rate of pediatric Mycoplasma pneumoniae isolates to erythromycin and azithromycin, with lower MICs observed for the 16-membered macrolide acetylspiramycin. These findings highlight the urgent need for alternative macrolide strategies and robust susceptibility testing in antimicrobial resistance research.

• Porcupine Inhibition as a Therapeutic Avenue in Sclerosteosi

  2026-08-05

  This article reviews a recent study demonstrating that pharmacological inhibition of Porcupine (PORCN) via LGK-974 effectively suppresses pathological bone overgrowth in sclerosteosis, a rare high bone mass disorder. The findings highlight the mechanistic and translational potential of PORCN inhibitors to modulate Wnt/β-catenin signaling and offer a novel, less invasive treatment approach for severe skeletal pathologies.

• miR-24-3p/Sp1/PI3K Axis in Doxorubicin-Induced Heart Failure

  2026-08-04

  This article analyzes recent evidence that miR-24-3p directly impairs cardiac function in doxorubicin-induced heart failure through targeted suppression of the Sp1/PI3K signaling pathway. Silencing miR-24-3p alleviates myocardial injury, highlighting the axis as a promising therapeutic target and a mechanistic bridge for future research on transcriptional regulation in cardiovascular models.

• Cyclophosphamide: Applied Workflows for Oncology Research

  2026-08-04

  Cyclophosphamide is a gold-standard alkylating chemotherapeutic agent, pivotal for apoptosis induction and immune modulation in cancer and transplantation research. This article delivers actionable protocols, advanced troubleshooting, and comparative insights to optimize experimental outcomes using Cyclophosphamide from APExBIO.

8053 records 3/537 page Previous Next 12345 下5页 Last page